Treatment of endometrial stromal tumors

We reviewed 31 cases of endometrial stromal tumors treated on the Gynecology Service at Memorial Sloan-Kettering Cancer Center from 1970 to 1984. Twenty-two patients had endolymphatic stromal myosis and 9 patients had endometrial stromal sarcoma. Twenty-six patients initially had disease confined to...

Full description

Saved in:
Bibliographic Details
Published inGynecologic oncology Vol. 36; no. 1; pp. 60 - 65
Main Authors Berchuck, Andrew, Rubin, Stephen C., Hoskins, William J., Saigo, Patricia E., Pierce, Virginia K., Lewis, John L.
Format Journal Article
LanguageEnglish
Published San Diego, CA Elsevier Inc 1990
Elsevier
Subjects
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Combined Modality Therapy
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Medical sciences
Middle Aged
Mitosis
Neoplasm Recurrence, Local - therapy
Ovariectomy
Sarcoma - therapy
Survival Rate
Tumors
Uterine Neoplasms - mortality
Uterine Neoplasms - pathology
Uterine Neoplasms - therapy
Human
Sarcoma
Stroma
Malignant tumor
Radiotherapy
Survival
Female genital diseases
Chemotherapy
Treatment
Uterus
Evolution
Female
Tumor
Endometrium
Online AccessGet full text

Cover

More Information
Summary:We reviewed 31 cases of endometrial stromal tumors treated on the Gynecology Service at Memorial Sloan-Kettering Cancer Center from 1970 to 1984. Twenty-two patients had endolymphatic stromal myosis and 9 patients had endometrial stromal sarcoma. Twenty-six patients initially had disease confined to the uterus. Following hysterectomy, 7 patients received various adjuvant therapies, but no active adjuvant regimen was identified. All 3 patients who presented with advanced endometrial stromal sarcoma died of rapidly progressive disease; only 2 of 6 patients with stage I endometrial stromal sarcoma developed recurrence. Among patients with endolymphatic stromal myosis, a higher recurrence rate was noted in patients with residual ovarian tissue (100%) than in those without residual ovarian tissue (43%). Fifteen patients were treated for recurrent disease (13 with endolymphatic stromal myosis, 2 with endometrial stromal sarcoma). Following attempts to resect disease surgically, objective responses were attained with both chemotherapy (57%) and radiation (40%). The median survival following treatment of recurrent disease was 46 months. Actuarial survival for all patients in this study was 76% at 5 years and 69% at 10 years.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0090-8258
1095-6859
DOI:10.1016/0090-8258(90)90109-X